Table 4.
NEI VFQ-25 score change between the exit visit and baseline
| NEI VFQ-25 subscales | All patients
|
Fixed Ozurdex (dexamethasone intravitreal implant)
|
PRN dexamethasone intravitreal implant
|
P-value |
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | ||
| GV | 1.89±17.3 | 1.67±16.9 | 2.13±17.8 | 0.917 |
| NA | 0.61±20.2 | 3.47±22.7 | −2.31±17.0 | 0.362 |
| DA | 3.43±19.5 | 9.28±19.2 | −2.17±18.3 | 0.008 |
| VSMH | 557±24.4 | 5.31±27.2 | 5.84±21.4 | 0.942 |
| VSRD | 0.27±27.2 | −0.26±29.1 | 0.82±25.3 | 0.734 |
| VSD | 2.48±25.5 | 1.74±27.2 | 3.26±24.0 | 0.813 |
| VSSF | 3.23±19.9 | 6.25±21.1 | 0±18.3 | 0.142 |
| D | 1.25±16.2 | 0±4.6 | 1.92±14.8 | 0.949 |
| CV | 3.68±20.3 | 7.81±25.9 | −0.53±11.0 | 0.045 |
| OP | −1.33±19.7 | 2.60±19.3 | −5.43±19.5 | 0.061 |
| PV | 0.79±27.5 | 4.69±27.1 | −3.26±27.7 | 0.138 |
| GH | −1.86±23.8 | 1.06±25.0 | −4.79±22.5 | 0.917 |
| Composite score (minus GH) | 3.39±14.2 | 6.68±14.7 | 0.09±13.0 | 0.065 |
Note: Bold values denote statistical significance.
Abbreviations: NEI VFQ-25, National Eye Institute Visual Function Questionnaire-25; PRN, pro re nata; GV, general vision; NA, near activities; DA, distance activities; VSMH, vision-specific mental health; VSRD, vision-specific role difficulties; VSD, vision-specific dependency; VSSF, vision-specific social functioning; D, driving; CV, color vision; OP, ocular pain; PV, peripheral vision; GH, general health; SD, standard deviation.